Document Detail


Circulating angiogenic proteins in trisomy 13.
MedLine Citation:
PMID:  16389038     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: Women who are carrying a trisomy 13 fetus are more prone to develop preeclampsia. Excess circulating soluble fms-like tyrosine kinase-1 has been implicated recently in the pathogenesis of preeclampsia. Since the fms-like tyrosine kinase-1/soluble fms-like tyrosine kinase-1 gene is located on chromosome 13q12, we hypothesized that the extra copy of this gene in trisomy 13 may lead to excess circulating soluble fms-like tyrosine kinase-1, reduced free placental growth factor level, and increased soluble fms-like tyrosine kinase-1/placental growth factor ratio. This may then contribute to the increased risk of preeclampsia that has been observed in these patients. Our objective was to characterize the maternal circulating angiogenic proteins in trisomy 13 pregnancies. STUDY DESIGN: Maternal serum samples of trisomy 13, 18, 21 and normal karyotype pregnancies were obtained from first and second trimester screening programs. We chose 17 cases of trisomy 13 that were matched for maternal age, freezer storage time, and parity with 85 normal karyotype control samples. Additionally, 20 cases of trisomy 18 and 17 cases of trisomy 21 were included. Cases and control samples were assayed for levels of soluble fms-like tyrosine kinase-1 and placental growth factor by enzyme-linked immunosorbent assay in a blinded fashion. Because of the skewed distributions of soluble fms-like tyrosine kinase-1 and placental growth factor, nonparametric analytic techniques were used, and the results are reported as median and ranges. RESULTS: In early pregnancy trisomy 13 cases and control samples, the median circulating soluble fms-like tyrosine kinase-1/placental growth factor ratios were 17.0 (range, 1.2-61.3) and 6.7 (range, 0.8-62.9), respectively (P = .003). The median soluble fms-like tyrosine kinase-1/placental growth factor ratios in trisomy 18 and 21 were 4.8 (range, 0.9-53.9) and 5.1 (range, 1.0-18.1), which were not significantly different than the control samples. Furthermore, the differences between trisomy 13 and control samples were more pronounced in the second trimester specimens than in the specimens from the first trimester. CONCLUSION: These data suggest that alterations in circulating angiogenic factors may be involved intimately in the pathogenesis of preeclampsia in trisomy 13. A larger clinical study that measures these factors longitudinally and correlates them with pregnancy outcomes is needed to further establish the link between trisomy 13, altered angiogenic factors, and preeclampsia.
Authors:
Yuval Bdolah; Glenn E Palomaki; Yuval Yaron; Tali Bdolah-Abram; Marlene Goldman; Richard J Levine; Benjamin P Sachs; James E Haddow; S Ananth Karumanchi
Related Documents :
9934978 - Molecular cytogenetic analysis of a de novo 5q31q33 deletion associated multiple congen...
1877618 - Ullrich-turner syndrome in mother and daughter: prenatal diagnosis of a 46,x,del(x)(p21...
3905068 - Any place for antenatal diagnosis in the third trimester of pregnancy?
8654308 - Fetal hepatic alpha-fetoprotein mrna expression in fetuses with trisomy 21 and 18 at 12...
22916558 - Promoting healthy timing and spacing of pregnancy with young married women in northern ...
23121458 - Are periodontal bacterial profiles and placental inflammatory infiltrate in pregnancy r...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  American journal of obstetrics and gynecology     Volume:  194     ISSN:  1097-6868     ISO Abbreviation:  Am. J. Obstet. Gynecol.     Publication Date:  2006 Jan 
Date Detail:
Created Date:  2006-01-03     Completed Date:  2006-04-10     Revised Date:  2009-11-25    
Medline Journal Info:
Nlm Unique ID:  0370476     Medline TA:  Am J Obstet Gynecol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  239-45     Citation Subset:  AIM; IM    
Affiliation:
Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Angiogenic Proteins / blood*
Case-Control Studies
Chromosomes, Human, Pair 13*
Chromosomes, Human, Pair 18
Down Syndrome
Enzyme-Linked Immunosorbent Assay
Female
Humans
Pregnancy / blood*
Pregnancy Proteins / blood
Pregnancy Trimester, First
Pregnancy Trimester, Second
Single-Blind Method
Trisomy*
Vascular Endothelial Growth Factor Receptor-1 / blood
Grant Support
ID/Acronym/Agency:
HL 079594/HL/NHLBI NIH HHS
Chemical
Reg. No./Substance:
0/Angiogenic Proteins; 0/Pregnancy Proteins; 144589-93-5/placenta growth factor; EC 2.7.10.1/Vascular Endothelial Growth Factor Receptor-1

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The effects of repeated corticosteroid administration on the neurogenesis in the neonatal rat.
Next Document:  Inhibitory effect of erythropoietin on contractility of human chorionic plate vessels.